Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Stock Elyse

2. Date of Event Requiring Statement (MM/DD/YYYY) 8/8/2019

3. Issuer Name and Ticker or Trading Symbol

Biohaven Pharmaceutical Holding Co Ltd. [BHVN]

(Last) (First) (Middle)

C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
Chief Medical Officer /

(Street)

NEW HAVEN, CT 06510

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	4/5/2027	Common Shares	37000	$10.82	D
Employee Stock Option (Right to Buy)	⁽²⁾	9/4/2027	Common Shares	10000	$37.54	D
Employee Stock Option (Right to Buy)	⁽³⁾	12/6/2027	Common Shares	42612	$20.79	D
Employee Stock Option (Right to Buy)	⁽⁴⁾	11/20/2028	Common Shares	65000	$32.42	D
Employee Stock Option (Right to Buy)	⁽⁵⁾	3/22/2029	Common Shares	6000	$50.85	D

Explanation of Responses:
(1)	The option became exercisable as to 18,500 of these shares on and prior to April 6, 2019 and becomes exercisable as to the remaining 18,500 shares on April 6, 2020, subject to the reporting person's continued service as of such date.
(2)	The option became exercisable as to 2,500 of these shares on September 5, 2018, with the remainder vesting in 3 equal installments on September 5, 2019, September 5, 2020 and September 5, 2021, subject to the reporting person's continuing service as of each applicable vesting date.
(3)	The option became exercisable as to 10,653 of these shares on December 7, 2018, with the remainder vesting in 3 equal installments on December 7, 2019, December 7, 2020 and December 7, 2021, subject to the reporting person's continuing service as of each applicable vesting date.
(4)	The option vests in 4 equal installments on the first, second, third and fourth anniversaries of November 20, 2018, in each case subject to the reporting person's continuing service as of each applicable vesting date.
(5)	This option vested as to all 6,000 shares on June 27, 2019.

Remarks:
Exhibit 24.1 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Stock Elyse C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN, CT 06510			Chief Medical Officer

Signatures
/s/ James Engelhart, Attorney-in-fact		8/19/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.